METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA
First Claim
1. A method of treating, preventing or ameliorating a cancer comprising administering to a patient in need thereof a Neutrokine-alpha antagonist in an amount effective to treat, prevent or ameliorate the cancer.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
-
Citations
20 Claims
- 1. A method of treating, preventing or ameliorating a cancer comprising administering to a patient in need thereof a Neutrokine-alpha antagonist in an amount effective to treat, prevent or ameliorate the cancer.
- 13. A method of inhibiting the activation of nuclear factor KB in a cancer cell comprising administering a Neutrokine-alpha antagonist.
- 18. A method of inhibiting the activation of nuclear factor KB in cancer cells to thereby induce radiation susceptibility therein, comprising the steps of treating said cells with an inhibitor of THANK protein in an amount effective to induce radiation sensitivity therein, wherein the THANK inhibitor is an antibody that recognizes THANK protein, and wherein said THANK protein is defined by the amino acid sequence of SEQ ID NO:
Specification